Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 13 of 13 for “"BRAF inhibitor"”.
-
Investigation of signalling pathways associated with the development of BRAF inhibitor resistance and treatment of melanoma
… It is the fifth most common cancer in UK. BRAF V600E mutation is observed in approximately 50% of melanomas and causes excessive stimulation of the MAPK signalling leading to proliferation, metastasis and invasion. In BRAF V600E positive mela-noma patients, BRAF is inhibited to prevent MAPK …
-
A Phase I Dose-Escalation Study of The Braf Inhibitor Vemurafenib In Combination With The Mtor Inhibitor Everolimus In Subjects With Advanced Cancer
… for the treatment of relapsed or refractory BRAF mutation positive malignant melanoma and is being investigated in various other malignancies. The RAS/RAF/MEK/ERK (MAPK) pathway is critical to cell proliferation in many human cancers. The mTOR inhibitors are well known to exert profound …
-
Transient Metabolic Alterations Induced by Chemotherapeutics in Cancer Persisters
… melanoma cells mediated by Vemurafenib (VEM), a BRAF inhibitor. Co-treatment with BRAF inhibitors is a common treatment strategy for melanoma cancer. However, how a BRAF inhibitor itself alters melanoma cell metabolism and mediates persister survival is not well understood. Our findings …
-
Leveraging copper chelators as targeted therapy for BRAFV600E mutant thyroid cancer
… have an oncogenic V600E mutation in the kinase BRAF, which leads to a constitutively active and oncogenic kinase. This mutation has been associated with as well as a 2.14-fold increase in recurrent/persistent disease. Excitingly, inhibitors against this mutant kinase or its substrates, the …
-
Epigenetic Modification as a Therapeutic Target in BRAFV600E-mutated Metastatic Colorectal Cancer
<p>Patients with BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer (mCRC) experience a worse prognosis and demonstrate only a 5% response rate to BRAF inhibitor treatment. In this study, adaptive resistance, and a potential combination of standard therapies in BRAF<sup>V600E</sup> CRC were …
-
Epigenetic Modulation In Braf Mutated Metastatic Colorectal Cancer
<p><strong>Introduction:</strong> BRAF V600E mutations are associated with poor clinical outcomes for patients with metastatic colorectal cancer (mCRC). Unlike other tumors with the same mutation, BRAF inhibitors are ineffective as monotherapy. CRC tumors with BRAF V600E mutations are associated …
-
Interrogation and control of mammalian transcription
… changes that can lead to the development of BRAF inhibitor resistance in BRAFV 600 mutant melanoma cells. The screen results highlighted a number of gene candidates that both confirm known BRAF inhibitor-resistance pathways and suggest novel mechanisms of action. SAM activators present a …
-
FROM NUCLEUS TO MITOCHONDRIA: INSIGHTS INTO THE ROLE OF TERT IN THE PROGRESSION OF PAPILLARY THYROID CARCINOMA
… we investigated the effect of PP2, a SRC kinase inhibitor, which is supposed to inhibit the pathway that allows for TERT nuclear export, on K1 cell proliferation. We found that TERT shuttled into the cytoplasm and in some cases to the mitochondria in response to OS increase either from H2O2 or …
-
The Role of the Mitogen Activated Protein Kinase Pathway in Cisplatin and Noise-Induced Hearing Loss
… both cisplatin and noise-induced hearing loss. Dabrafenib, a BRAF inhibitor, and trametinib, a MEK1/2 inhibitor, protected from cisplatin-induced hearing loss in a translational mouse model of cisplatin ototoxicity while dabrafenib, trametinib, and tizaterkib, an ERK1/2 inhibitor, protected from …
-
Exploiting tumour cell dependency on pro-survival BCL2 proteins with BH3 mimetics
… in human cancer, with mutations in KRAS and BRAF commonly occurring in cancers of the pancreas, skin, and colon, among others. Indeed, BRAF and MEK1/2 inhibitors are approved for the treatment of BRAF-mutant malignant melanoma and are improving patient outcomes. However, the development of …
-
Unbiased assessment of P-gp efflux towards designing blood—brain barrier penetrant compounds
The student, Aya Kelly, accepted the attached license on 2022-04-15 at 10:24.
-
Overcoming Acquired Resistance to BRAF Inhibitors by Novel Synergistic Drug Combination and Discovery of Novel Smac Mimetics as Selective Survivin Inhibitors
… clinical resistance to vemurafenib, a selective BRAFV600E inhibitor, arises frequently after short term chemotherapy. Since the inhibitions of targets in the RAFMEK-ERK pathway result in G0/G1 cell cycle arrest, vemurafenib-resistant cancer cells are expected to escape this cell cycle arrest and …